371
Participants
Start Date
October 20, 2015
Primary Completion Date
September 17, 2018
Study Completion Date
February 25, 2025
gilteritinib
tablet, oral
LoDAC (Low Dose Cytarabine)
subcutaneous (SC) or intravenous (IV) injection
Azacitidine
SC or IV injection
MEC (Mitoxantrone, Etoposide, Cytarabine)
IV injection
FLAG-IDA (Granulocyte-Colony Stimulating Factor (G-CSF), Fludarabine, Cytarabine, Idarubicin)
SC (G-CSF) and IV (Fludarabine, Cytarabine, Idarubicin) injection
Site TW88606, Kaohsiung City
Site TW88611, Taipei
Site TW88602, Taipei
Site TW88608, Taichung
Site TW88601, Tainan City
Site BE32002, Yvoir
Site TW88603, Taipei
Site US10037, New York
Site US10008, New York
Site US10013, New York
Site US10072, New York
Site TW88610, Taipei
Site US10046, Syracuse
Site US10001, Buffalo
Site ES34016, Girona
Site US10041, Hershey
Site US10010, Philadelphia
Site US10080, Philadelphia
Site IT39001, Milan
Site IT39002, Varese
Site US10005, Baltimore
Site IT39010, Brescia
Site IT39011, Pavia
Site US10078, Winston-Salem
Site US10024, Durham
Site US10014, Charleston
Site FR33013, Brest
Site US10081, Atlanta
Site FR33008, Toulouse
Site IL97209, Haifa
Site US10045, Gainesville
Site TW88605, Taoyuan District
Site FR33009, Pessac
Site FR33014, Rennes
Site DE49003, Marburg
Site ES34014, Salamanca
Site IT39005, Bologna
Site US10074, Louisville
Site TW88609, Taichung
Site US10084, Columbus
Site US10044, Cleveland
Site ES34017, Valencia
Site US10087, Detroit
Site IL97206, Petah Tikva
Site US10035, Milwaukee
Site US10057, Minneapolis
Site FR33010, Lille
Site US10006, Chicago
Site US10075, Westwood
Site US10048, New Orleans
Site DE49010, Tübingen
Site US10058, Oklahoma City
Site IL97208, Rehovot
Site FR33002, Le Chesnay
Site IL97201, Ashkelon
Site DE49002, München
Site TW88604, Kaohsiung City
Site IT39004, Palermo
Site IL97203, Jerusalem
Site IL97210, Jerusalem
Site US10076, Orange
Site US10073, San Francisco
Site KR82001, Seoul
Site KR82002, Seoul
Site KR82005, Suwon
Site KR82010, Busan
Site US10011, Birmingham
Site US10012, Los Angeles
Site US10067, New Haven
Site US10034, Boston
Site US10022, Boston
Site US10085, Boston
Site US10023, Lebanon
Site US10027, Hackensack
Site US10077, New Brunswick
Site US10063, Nashville
Site CA15004, Edmonton
Site CA15001, Hamilton
Site CA15015, Toronto
Site CA15003, Montreal
Site DE49009, Dresden
Site DE49011, Leipzig
Site IT39007, Roma
Site JP81002, Nagoya
Site JP81010, Narita
Site JP81026, Yoshida-gun
Site JP81016, Sapporo
Site JP81018, Kobe
Site JP81017, Tsukuba
Site JP81009, Isehara
Site JP81006, Yokohama
Site JP81012, Sendai
Site JP81007, Kurashiki
Site JP81014, Sayama
Site JP81020, Kawagoe
Site JP81027, Shimotsuke
Site JP81005, Chuo-ku
Site JP81004, Shinagawa-ku
Site JP81022, Shinjuku-ku
Site JP81023, Akita
Site JP81021, Aomori
Site JP81013, Kumamoto
Site JP81025, Kyoto
Site JP81008, Nagasaki
Site JP81024, Okayama
Site JP81011, Osaka
Site PL48002, Gdansk
Site PL48005, Opole
Site PL48004, Wroclaw
Site KR82009, Goyang
Site KR82003, Jeollanam-do
Site KR82007, Seoul
Site KR82004, Seoul
Site KR82008, Seoul
Site KR82011, Seoul
Site ES34009, Badalona
Site ES34011, Barcelona
Site ES34012, Barcelona
Site ES34010, Barcelona
Site ES34005, L'Hospitalet de Llobregat
Site TR90001, Ankara
Site TR90004, Ankara
Site GB44014, Bournemouth
Site GB44013, Harrow
Site GB44003, Manchester
Site GB44015, Plymouth
Astellas Pharma Global Development, Inc.
INDUSTRY